CollPlant Biotechnologies (CLGN) Debt Ratio (2017 - 2019)
CollPlant Biotechnologies (CLGN) posted Debt Ratio of 0.0 for Q4 2019, down 99.5% on a QoQ basis from 0.45 in Q4 2017.
CollPlant Biotechnologies (CLGN) Debt Ratio (2017 - 2019) Analysis & Trends
CollPlant Biotechnologies' Debt Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q4 2019.
- Quarterly Debt Ratio changed N/A year-over-year to 0.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was 0.0 (changed N/A YoY) and the FY2019 annual result came in at 0.0, changed N/A from the prior year.
- Debt Ratio was 0.0 for Q4 2019 at CollPlant Biotechnologies, down from 0.45 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.45 in Q4 2017 and bottomed at 0.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 1.41 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 0.11 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 0.00 |
| Dec 31, 2017 | 0.45 |